Cargando…
Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression
Metastatic prostate cancer is a leading cause of cancer-related death in men worldwide. We have recently discovered that IL-30 shapes the microenvironment of prostate cancer and tumor-draining lymph nodes to favor tumor progression. IL-30 supports tumor growth in vitro, and IL-30 expression in prost...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988120/ https://www.ncbi.nlm.nih.gov/pubmed/24741467 http://dx.doi.org/10.4161/onci.27618 |
| _version_ | 1782311983181201408 |
|---|---|
| author | Di Carlo, Emma |
| author_facet | Di Carlo, Emma |
| author_sort | Di Carlo, Emma |
| collection | PubMed |
| description | Metastatic prostate cancer is a leading cause of cancer-related death in men worldwide. We have recently discovered that IL-30 shapes the microenvironment of prostate cancer and tumor-draining lymph nodes to favor tumor progression. IL-30 supports tumor growth in vitro, and IL-30 expression in prostate cancer patients is associated with high tumor grade and metastatic stage of disease. Thus, IL-30 may constitute a valuable target for modern therapeutic approaches to hamper prostate cancer progression. |
| format | Online Article Text |
| id | pubmed-3988120 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Landes Bioscience |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39881202014-04-16 Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression Di Carlo, Emma Oncoimmunology Author's View Metastatic prostate cancer is a leading cause of cancer-related death in men worldwide. We have recently discovered that IL-30 shapes the microenvironment of prostate cancer and tumor-draining lymph nodes to favor tumor progression. IL-30 supports tumor growth in vitro, and IL-30 expression in prostate cancer patients is associated with high tumor grade and metastatic stage of disease. Thus, IL-30 may constitute a valuable target for modern therapeutic approaches to hamper prostate cancer progression. Landes Bioscience 2014-01-06 /pmc/articles/PMC3988120/ /pubmed/24741467 http://dx.doi.org/10.4161/onci.27618 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | Author's View Di Carlo, Emma Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression |
| title | Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression |
| title_full | Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression |
| title_fullStr | Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression |
| title_full_unstemmed | Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression |
| title_short | Interleukin-30: A novel microenvironmental hallmark of prostate cancer progression |
| title_sort | interleukin-30: a novel microenvironmental hallmark of prostate cancer progression |
| topic | Author's View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988120/ https://www.ncbi.nlm.nih.gov/pubmed/24741467 http://dx.doi.org/10.4161/onci.27618 |
| work_keys_str_mv | AT dicarloemma interleukin30anovelmicroenvironmentalhallmarkofprostatecancerprogression |